In his new role, Joe will lead the expansion of the company’s sales and support activities for the US market to address the growing demand for new alternative methodologies (NAMs) in preclinical drug discovery.
Following several key senior appointments in the UK last year, Joe’s appointment will strengthen CN Bio’s growth in another of its key markets (the US), providing a local source of expertise and support for customers looking to harness the company’s PhysioMimix OOC range of MPS.
During the past year, the global demand for NAMs has accelerated, particularly in the US following the enactment of the FDA Modernization Act 2.01.
Joe’s sales expertise will be crucial for meeting this growing demand; working alongside the leadership team to drive the commercial expansion strategy, whilst supporting customers to improve the human relevance of preclinical workflows and reduce animal model reliance.
Joe Parisi, US Director of Sales, CN Bio, commented: “The potential offered by CN Bio’s PhysioMimix range, substantiated by the company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve efficiency and minimise drug failures."
"In my new role, I look forward to harnessing my experience within the sector to support the design and implementation of a commercial strategy that will enable us to meet the significant demand for animal model alternatives here in the US.”
Dr Paul Brooks, Chief Executive Officer, said: “It is great to welcome Joe to the team. Throughout his career, he has repeatedly demonstrated his expertise in biotech sales, with a proven history of success across companies at all stages of growth and commercialisation."
"Joe’s appointment represents an important milestone in CN Bio’s growth, having successfully built a strong international presence and now looking to expand this further into the US, a key market for innovative drug discovery.”
